Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.61 |
| ▸ | PARP1 | P09874 | 5/20 | 0.54 |
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SI | P14410 | 1/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28027630 | 0.88 | HPSE (0.65) | CBFBALDH1A1TP53CYP3A4CYP2D6 | |
| SCHEMBL29625822 | 0.88 | HPSE (0.65) | CBFBALDH1A1TP53CYP3A4CYP2D6 | |
| SCHEMBL20597842 | 0.85 | MGAM (0.68) | CBFBALDH1A1TP53CYP3A4CYP2D6 | |
| SCHEMBL5202010 | 0.85 | CBFB (0.58) | CBFBALDH1A1TP53CYP3A4CYP2D6 | |
| SCHEMBL124275 | 0.84 | CBFB (0.68) | CBFBALDH1A1TP53CYP3A4CYP2D6 | |
| SCHEMBL124235 | 0.84 | CBFB (0.68) | CBFBALDH1A1TP53CYP3A4CYP2D6 | |
| SCHEMBL4611125 | 0.83 | ALDH1A1 (0.55) | CBFBALDH1A1TP53CYP3A4CYP2D6 | |
| SCHEMBL4420446 | 0.83 | ALDH1A1 (0.55) | CBFBALDH1A1TP53CYP3A4CYP2D6 | |
| SCHEMBL9045167 | 0.83 | PARP1 (0.60) | CBFBALDH1A1TP53CYP3A4CYP2D6 | |
| SCHEMBL125229 | 0.83 | CBFB (1.00) | CBFBALDH1A1TP53CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | claimed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | claimed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | claimed |
| EP-2240023-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Siga Technologies, Inc. (US) | 2010-10-20 | — | — | EP | claimed |
| WO-2009123776-A2 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2009-10-08 | — | — | WO | claimed |
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | SIGA TECHNOLOGIES, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623347-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100245-A1 | Antiviral Drugs for Treatment of Arenvirus Infection | HAVCR2, ZC3HAV1, SARS1 | CBFB 1223/4885ALDH1A1 2058/4885TP53 1656/4885 |
| US-20110027227-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | ZC3HAV1, EIF2AK2, SARS1 | CBFB 3019/4885ALDH1A1 2238/4885TP53 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.